» Articles » PMID: 36802023

Clinical Application of Artificial Intelligence Algorithm for Prediction of One-year Mortality in Heart Failure Patients

Abstract

Risk prediction for heart failure (HF) using machine learning methods (MLM) has not yet been established at practical application levels in clinical settings. This study aimed to create a new risk prediction model for HF with a minimum number of predictor variables using MLM. We used two datasets of hospitalized HF patients: retrospective data for creating the model and prospectively registered data for model validation. Critical clinical events (CCEs) were defined as death or LV assist device implantation within 1 year from the discharge date. We randomly divided the retrospective data into training and testing datasets and created a risk prediction model based on the training dataset (MLM-risk model). The prediction model was validated using both the testing dataset and the prospectively registered data. Finally, we compared predictive power with published conventional risk models. In the patients with HF (n = 987), CCEs occurred in 142 patients. In the testing dataset, the substantial predictive power of the MLM-risk model was obtained (AUC = 0.87). We generated the model using 15 variables. Our MLM-risk model showed superior predictive power in the prospective study compared to conventional risk models such as the Seattle Heart Failure Model (c-statistics: 0.86 vs. 0.68, p < 0.05). Notably, the model with an input variable number (n = 5) has comparable predictive power for CCE with the model (variable number = 15). This study developed and validated a model with minimized variables to predict mortality more accurately in patients with HF, using a MLM, than the existing risk scores.

Citing Articles

Rationale and Design of a Multicenter Trial on Exploratory Analysis of the Effects of Advance Care Planning Guided by the Prediction Program of Heart Failure Prognosis on Quality of Life in Patients With Heart Failure - ACQUAINT-Trial.

Takahama H, Kitai T, Nakagawa S, Takegami M, Hamatani Y, Nakamoto K Circ Rep. 2024; 6(7):276-280.

PMID: 38989104 PMC: 11233169. DOI: 10.1253/circrep.CR-24-0041.


Advances in the design, generation, and application of tissue-engineered myocardial equivalents.

Bernava G, Iop L Front Bioeng Biotechnol. 2023; 11:1247572.

PMID: 37811368 PMC: 10559975. DOI: 10.3389/fbioe.2023.1247572.

References
1.
Takahama H, Kitakaze M . Pathophysiology of cardiorenal syndrome in patients with heart failure: potential therapeutic targets. Am J Physiol Heart Circ Physiol. 2017; 313(4):H715-H721. DOI: 10.1152/ajpheart.00215.2017. View

2.
Takahama H, Yokoyama H, Kada A, Sekiguchi K, Fujino M, Funada A . Extent of heart rate reduction during hospitalization using beta-blockers, not the achieved heart rate itself at discharge, predicts the clinical outcome in patients with acute heart failure syndromes. J Cardiol. 2012; 61(1):58-64. DOI: 10.1016/j.jjcc.2012.08.014. View

3.
Fujino M, Takahama H, Hamasaki T, Sekiguchi K, Kusano K, Anzai T . Risk stratification based on nutritional screening on admission: Three-year clinical outcomes in hospitalized patients with acute heart failure syndrome. J Cardiol. 2016; 68(5):392-398. DOI: 10.1016/j.jjcc.2016.05.004. View

4.
Levy W, Mozaffarian D, Linker D, Sutradhar S, Anker S, Cropp A . The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006; 113(11):1424-33. DOI: 10.1161/CIRCULATIONAHA.105.584102. View

5.
Shiraishi Y, Kohsaka S, Nagai T, Goda A, Mizuno A, Nagatomo Y . Validation and Recalibration of Seattle Heart Failure Model in Japanese Acute Heart Failure Patients. J Card Fail. 2018; 25(7):561-567. DOI: 10.1016/j.cardfail.2018.07.463. View